281 related articles for article (PubMed ID: 21762078)
1. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia.
Mummery A; Narendran A; Lee KY
Curr Cancer Drug Targets; 2011 Sep; 11(7):882-93. PubMed ID: 21762078
[TBL] [Abstract][Full Text] [Related]
2. Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents.
Sonnemann J; Gruhn B; Wittig S; Becker S; Beck JF
Br J Haematol; 2012 Sep; 158(5):664-6. PubMed ID: 22686282
[No Abstract] [Full Text] [Related]
3. Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.
Xu H; Yu H; Jin R; Wu X; Chen H
Cells; 2021 Nov; 10(12):. PubMed ID: 34943855
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
5. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
6. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
Bai Y; Ahmad D; Wang T; Cui G; Li W
Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
[TBL] [Abstract][Full Text] [Related]
7. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
[No Abstract] [Full Text] [Related]
9. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Markozashvili D; Ribrag V; Vassetzky YS
Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitors in Cancer Therapy.
Sun Y; Sun Y; Yue S; Wang Y; Lu F
Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin enhances the efficacy of cytarabine
Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
[No Abstract] [Full Text] [Related]
13. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 10, a potential epigenetic target for therapy.
Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33997894
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
17. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
19. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
Schobert R; Biersack B
Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
[TBL] [Abstract][Full Text] [Related]
20. The role of HDACs inhibitors in childhood and adolescence acute leukemias.
Masetti R; Serravalle S; Biagi C; Pession A
J Biomed Biotechnol; 2011; 2011():148046. PubMed ID: 21318168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
